• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Structure of the Hematological Cancer Market and Its Perspectives

Posted on: Thursday, 3 November 2005, 09:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c26910) has announced the addition of Hematological Cancer Therapeutics: Pipelines and Competition to their offering.

Blood cancers include leukemia, lymphoma, and multiple myeloma. Collectively, these cancers are the fifth most commonly occurring cancers and the second leading cause of cancer death. Hematological Cancer Therapeutics: Pipelines and Competition provides a realistic assessment of how newly-approved drugs and candidates in development will impact this sector of the cancer treatment field within the next decade.

The report reviews the activities of the leading companies in this arena and provides a market assessment for all companies currently competing in or contemplating entering the field.

The major strides are being made in small specialist companies with a broad range of compounds in Phases I- III. However, the potential exists for large international companies to enter the market as candidates from niche companies reach later stages and prove useful in a broader context of cancer, as very frequently is the case.

Indeed, many emerging novel agents, based on the identification of genetic lesions and aberrant signaling pathways, promise to improve upon standard therapies. Currently, therapy of blood cancers is dominated by what hematologists call therapy ladders--sequential uses of combination protocols consisting of drugs that have been available for a long time and are frequently also used for the treatment of solid tumors. However, this scenario will rapidly become more diverse as new therapeutic options reach the market.

Hematological Cancer Therapeutics: Pipelines and Competition:

- Characterizes hematological cancers and the use of various diagnostic technologies in conjunction with therapy selection and disease monitoring.

- Reviews newly licensed or advanced clinical-stage compounds--antimetabolites, inhibitors of DNA unwinding or transcription, or inhibitors of kinase-modulated intracellular pathways--under development at a multitude of small oncology companies for leukemias and myelodysplastic syndromes, lymphomas (Hodgkin's disease, non-Hodgkin's lymphoma, mantle cell lymphoma), and multiple myeloma. Promising candidates include Celgene's Revlimid, a thalidomide analog in Phase III for myelodysplastic syndrome and multiple myeloma, and Millennium Pharmaceutical's Velcade, a proteasome inhibitor, which has been gathering indications for multiple myeloma since May 2003.

- Projects which market segments will experience the most dynamic growth and evaluates market growth potential by cancer type.

- Weighs the potential of kinase-associated drugs to expand the market for acute myeloid leukemia (AML).

Companies Mentioned:

- Actinium Pharmaceuticals, Inc.

- BioCryst Pharmaceuticals, Inc.

- Celgene Corporation

- Cell Genesys, Inc.

- Cell Therapeutics, Inc.

- Genencor International, Inc.

- Inex Pharmaceuticals Corporation

- Lorus Therapeutics, Inc.

- Pharmion Corporation

- Vion Pharmaceuticals, Inc.

Contents Include:

Chapter 1. Blood Cell Malignancies: Disease Characteristics and Epidemiology

Chapter 2. Oncogenes, Translocations, and Surface Antigens: Keys to Diagnosis and Rational Therapy

Chapter 3. Current Therapies and Unmet Need

Chapter 4. Newly-Approved Drugs and Candidates in Development

Chapter 5. Structure of the Hematological Cancer Market and Its Perspectives

Chapter 6. Company Profiles

References

Glossary

Index

Tables & Figures

For more information visit http://www.researchandmarkets.com/reports/c26910

Source: Business Wire

More News in this Category